Literature DB >> 18991856

Dopamine disposition in the presynaptic process regulates the severity of methamphetamine-induced neurotoxicity.

Donald M Kuhn1, Dina M Francescutti-Verbeem, David M Thomas.   

Abstract

Methamphetamine (METH) is well known for its ability to cause damage to dopamine (DA) nerve endings of the striatum. The mechanisms by which METH causes neurotoxicity are not fully understood, but likely candidates are increased oxidative and nitrosative stress and mitochondrial dysfunction. Microglial activation is also emerging as an important element of the METH neurotoxic cascade, and it appears that extensive cross-talk between these cells and DA nerve endings is an early event in this process. It may seem paradoxical, but DA itself is also thought to be an essential factor in the neuronal damaging effects of METH, but issues relating to its precise role in this regard remain unanswered. We present in this overview a summary of studies that tested how alterations in the disposition of presynaptic DA (injections of reserpine, L-DOPA, or clorgyline) modulate METH neurotoxicity. In all cases, these drugs significantly increased the magnitude of microglial activation as well as the severity of damage to striatal DA nerve endings caused by METH. The enhancement of METH effects in striatum by reserpine, L-DOPA, and clorgyline persisted for 14 days and showed no evidence of recovery. These data establish that subtle shifts in the newly synthesized pool of DA can cause substantial changes in the severity of METH-induced neurotoxicity. DA released into the synapse by METH is very likely the source of downstream reactants that provoke microglial activation and the ensuing damage to DA nerve endings.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18991856      PMCID: PMC2593915          DOI: 10.1196/annals.1432.026

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  52 in total

1.  Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase.

Authors:  S Z Imam; G D Newport; Y Itzhak; J L Cadet; F Islam; W Slikker; S F Ali
Journal:  J Neurochem       Date:  2001-02       Impact factor: 5.372

Review 2.  Amphetamine neurotoxicity: cause and consequence of oxidative stress.

Authors:  Bryan K Yamamoto; Michael G Bankson
Journal:  Crit Rev Neurobiol       Date:  2005

3.  Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice.

Authors:  F Fumagalli; R R Gainetdinov; Y M Wang; K J Valenzano; G W Miller; M G Caron
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

4.  Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers.

Authors:  N D Volkow; L Chang; G J Wang; J S Fowler; M Leonido-Yee; D Franceschi; M J Sedler; S J Gatley; R Hitzemann; Y S Ding; J Logan; C Wong; E N Miller
Journal:  Am J Psychiatry       Date:  2001-03       Impact factor: 18.112

5.  Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamine.

Authors:  David M Thomas; Donald M Kuhn
Journal:  J Neurochem       Date:  2005-02       Impact factor: 5.372

6.  Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage.

Authors:  Donald M Kuhn; Dina M Francescutti-Verbeem; David M Thomas
Journal:  Ann N Y Acad Sci       Date:  2006-08       Impact factor: 5.691

7.  Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease.

Authors:  D M Kuhn; R E Arthur; D M Thomas; L A Elferink
Journal:  J Neurochem       Date:  1999-09       Impact factor: 5.372

8.  Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action.

Authors:  E A Fon; E N Pothos; B C Sun; N Killeen; D Sulzer; R H Edwards
Journal:  Neuron       Date:  1997-12       Impact factor: 17.173

9.  Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine.

Authors:  M J LaVoie; T G Hastings
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

10.  Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter.

Authors:  F Fumagalli; R R Gainetdinov; K J Valenzano; M G Caron
Journal:  J Neurosci       Date:  1998-07-01       Impact factor: 6.167

View more
  21 in total

Review 1.  Glial modulators as potential treatments of psychostimulant abuse.

Authors:  Patrick M Beardsley; Kurt F Hauser
Journal:  Adv Pharmacol       Date:  2014

2.  Enhanced neurodegeneration after a high dose of methamphetamine in adenosine A3 receptor null mutant mice.

Authors:  H Shen; Y Luo; S-J Yu; Y Wang
Journal:  Neuroscience       Date:  2011-08-10       Impact factor: 3.590

3.  Differential effects of binge methamphetamine injections on the mRNA expression of histone deacetylases (HDACs) in the rat striatum.

Authors:  Oluwaseyi Omonijo; Pawaris Wongprayoon; Bruce Ladenheim; Michael T McCoy; Piyarat Govitrapong; Subramaniam Jayanthi; Jean Lud Cadet
Journal:  Neurotoxicology       Date:  2014-10-27       Impact factor: 4.294

4.  Mephedrone, an abused psychoactive component of 'bath salts' and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum.

Authors:  Mariana Angoa-Pérez; Michael J Kane; Dina M Francescutti; Katherine E Sykes; Mrudang M Shah; Abiy M Mohammed; David M Thomas; Donald M Kuhn
Journal:  J Neurochem       Date:  2012-02-09       Impact factor: 5.372

5.  Methamphetamine potentiates HIV-1gp120-induced microglial neurotoxic activity by enhancing microglial outward K+ current.

Authors:  Jianuo Liu; Enquan Xu; Guihua Tu; Han Liu; Jiangtao Luo; Huangui Xiong
Journal:  Mol Cell Neurosci       Date:  2017-05-25       Impact factor: 4.314

6.  Ginsenoside Re rescues methamphetamine-induced oxidative damage, mitochondrial dysfunction, microglial activation, and dopaminergic degeneration by inhibiting the protein kinase Cδ gene.

Authors:  Eun-Joo Shin; Seung Woo Shin; Thuy-Ty Lan Nguyen; Dae Hun Park; Myung-Bok Wie; Choon-Gon Jang; Seung-Yeol Nah; Byung Wook Yang; Sung Kwon Ko; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Mol Neurobiol       Date:  2014-01-16       Impact factor: 5.590

7.  Assessing the role of dopamine in the differential neurotoxicity patterns of methamphetamine, mephedrone, methcathinone and 4-methylmethamphetamine.

Authors:  John H Anneken; Mariana Angoa-Perez; Girish C Sati; David Crich; Donald M Kuhn
Journal:  Neuropharmacology       Date:  2017-08-26       Impact factor: 5.250

8.  Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA.

Authors:  Mariana Angoa-Pérez; Michael J Kane; Denise I Briggs; Dina M Francescutti; Catherine E Sykes; Mrudang M Shah; David M Thomas; Donald M Kuhn
Journal:  J Neurochem       Date:  2013-01-08       Impact factor: 5.372

Review 9.  Methamphetamine toxicity and messengers of death.

Authors:  Irina N Krasnova; Jean Lud Cadet
Journal:  Brain Res Rev       Date:  2009-03-25

10.  Effects of combined treatment with mephedrone and methamphetamine or 3,4-methylenedioxymethamphetamine on serotonin nerve endings of the hippocampus.

Authors:  Mariana Angoa-Pérez; Michael J Kane; Nieves Herrera-Mundo; Dina M Francescutti; Donald M Kuhn
Journal:  Life Sci       Date:  2013-07-24       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.